{
    "clinical_study": {
        "@rank": "65344", 
        "arm_group": [
            {
                "arm_group_label": "Prasugrel", 
                "arm_group_type": "Experimental", 
                "description": "3 months treatment with 10 mg prasugrel"
            }, 
            {
                "arm_group_label": "Clopidogrel", 
                "arm_group_type": "Active Comparator", 
                "description": "3 months treatment with clopidogrel 75 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "To test the vasoactive and anti-inflammatory effects of prasugrel in patients with acute\n      coronary syndrome endothelial function -as a surrogate parameter of NO bioavailability- and\n      different markers of inflammation, oxidative stress and platelet activation will be assessed\n      in patients with unstable angina."
        }, 
        "brief_title": "Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Coronary Syndrome", 
            "Unstable Angina", 
            "Platelet Inhibition"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Angina, Unstable", 
                "Acute Coronary Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Acute coronary syndrome, unstable angina\n\n          -  planned percutaneous coronary intervention\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  - Age < 18 years or \u226575 years\n\n          -  Body weight < 60 kg\n\n          -  STEMI, NSTEMI\n\n          -  Cardiogenic shock at the time of randomization\n\n          -  Refractory ventricular arrhythmias\n\n          -  Congestive heart failure (NYHA IV)\n\n          -  Increased risk of bleeding\n\n          -  Active internal bleeding or history of hemorrhagic diathesis\n\n          -  History of TIA, ischemic or hemorrhagic stroke\n\n          -  Intracranial neoplasm, aneurysm and arteriovenous malformation\n\n          -  INR > 1.5 at screening\n\n          -  Platelets < 100,000/ml\n\n          -  Anemia (Hb < 10 g/dl) at screening\n\n          -  One or more doses of a thienopyridine 5 d or less before PCI\n\n          -  Oral anticoagulation which cannot be safely discontinued for the duration of the\n             study\n\n          -  One or more doses of a thienopyridine 5 d or less before PCI\n\n          -  Treatment within the last 30 d with an investigational drug or are presently enrolled\n             in another drug or device study\n\n          -  Women who are known to be pregnant, have given birth within the past 90 d, or are\n             breast-feeding\n\n          -  Concomitant medical illness that in the opinion of the investigator is associated\n             with reduced survival over the expected treatment period\n\n          -  Known severe hepatic dysfunction\n\n          -  Any condition associated with poor treatment compliance, including alcoholism, mental\n             illness, or drug dependence\n\n          -  Intolerance of or allergy to aspirin, ticlopidine, or clopidogrel"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01774838", 
            "org_study_id": "Uni-Koeln-1649"
        }, 
        "intervention": {
            "arm_group_label": [
                "Prasugrel", 
                "Clopidogrel"
            ], 
            "description": "3 months treatment", 
            "intervention_name": "Prasugrel or Clopidogrel", 
            "intervention_type": "Drug", 
            "other_name": "Efient / Plavix"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Clopidogrel", 
                "Prasugrel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 21, 2013", 
        "location": {
            "contact": {
                "email": "tanja.rudolph@uk-koeln.de", 
                "last_name": "Tanja Rudolph, MD", 
                "phone": "0049221478323", 
                "phone_ext": "96"
            }, 
            "facility": {
                "address": {
                    "city": "Cologne", 
                    "country": "Germany", 
                    "zip": "50937"
                }, 
                "name": "Cardiology, University Hospital of Cologne"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "tanja.rudolph@uk-koeln.de", 
            "last_name": "Tanja Rudolph, MD", 
            "phone": "0049221478323", 
            "phone_ext": "96"
        }, 
        "overall_contact_backup": {
            "email": "stephan.baldus@uk-koeln.de", 
            "last_name": "Stephan Baldus, MD", 
            "phone": "004922147832511"
        }, 
        "overall_official": {
            "affiliation": "University Hospital of Cologne", 
            "last_name": "Tanja Rudolph, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Federal Institute for Drugs and Medicinal Devices : 'Germany'", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is the change of endothelial function given in % from baseline to 3 months after therapy with prasugrel versus clopidogrel.", 
            "measure": "Assessment of endothelial function (FMD) via high-resolution ultrasound (Sonoline G50, 12 MHz linear array transducer, Siemens, Germany) by experienced sonographer", 
            "safety_issue": "No", 
            "time_frame": "baseline and after 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01774838"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Cologne", 
            "investigator_full_name": "Tanja Rudolph", 
            "investigator_title": "Consultant", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Cologne", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Cologne", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}